Next Article in Journal
Colonized Sabethes cyaneus, a Sylvatic New World Mosquito Species, Shows a Low Vector Competence for Zika Virus Relative to Aedes aegypti
Previous Article in Journal
Molecular Characterization and Geographic Distribution of a Mymonavirus in the Population of Botrytis cinerea
Open AccessArticle

Potential Therapeutic Agents for Feline Calicivirus Infection

1
School of Biotechnology and Biomolecular Sciences, Faculty of Science, University of New South Wales, Sydney, NSW 2052, Australia
2
Laboratório de Virologia Comparada e Ambiental, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro 21040-900, Brazil
*
Author to whom correspondence should be addressed.
Viruses 2018, 10(8), 433; https://doi.org/10.3390/v10080433
Received: 1 August 2018 / Revised: 14 August 2018 / Accepted: 15 August 2018 / Published: 16 August 2018
(This article belongs to the Section Antivirals & Vaccines)
Feline calicivirus (FCV) is a major cause of upper respiratory tract disease in cats, with widespread distribution in the feline population. Recently, virulent systemic diseases caused by FCV infection has been associated with mortality rates up to 50%. Currently, there are no direct-acting antivirals approved for the treatment of FCV infection. Here, we tested 15 compounds from different antiviral classes against FCV using in vitro protein and cell culture assays. After the expression of FCV protease-polymerase protein, we established two in vitro assays to assess the inhibitory activity of compounds directly against the FCV protease or polymerase. Using this recombinant enzyme, we identified quercetagetin and PPNDS as inhibitors of FCV polymerase activity (IC50 values of 2.8 μM and 2.7 μM, respectively). We also demonstrate the inhibition of FCV protease activity by GC376 (IC50 of 18 µM). Using cell culture assays, PPNDS, quercetagetin and GC376 did not display antivirals effects, however, we identified nitazoxanide and 2′-C-methylcytidine (2CMC) as potent inhibitors of FCV replication, with EC50 values in the low micromolar range (0.6 μM and 2.5 μM, respectively). In conclusion, we established two in vitro assays that will accelerate the research for FCV antivirals and can be used for the high-throughput screening of direct-acting antivirals. View Full-Text
Keywords: feline calicivirus; antivirals; nucleoside analogues; non-nucleoside inhibitors; protease inhibitors feline calicivirus; antivirals; nucleoside analogues; non-nucleoside inhibitors; protease inhibitors
Show Figures

Graphical abstract

MDPI and ACS Style

Fumian, T.M.; Tuipulotu, D.E.; Netzler, N.E.; Lun, J.H.; Russo, A.G.; Yan, G.J.H.; White, P.A. Potential Therapeutic Agents for Feline Calicivirus Infection. Viruses 2018, 10, 433.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop